| Assessment Status | Full HTA Assessment |
| HTA ID | - |
| Drug | Nilotinib CML resistant/intolerant to imatinib |
| Brand | Tasigna® |
| Indication | For the treatment of chronic phase CML. |
| Assessment Process | |
| Full submission received from Applicant | 03/01/2008 |
| NCPE assessment completed | 25/02/2008 |
| NCPE assessment outcome | Reimbursement not recommended |
The cost-effectiveness of nilotinib compared to dasatinib, in patients resistant to imatinib has not been demonstrated.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
